# Nature Medicine

Source: https://onco.cc/journals/nature-medicine/  
OnCo record `nature-medicine` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nature Medicine is Nature's clinical journal and now a top venue for early-phase and biomarker-rich cancer trials, medical AI studies and cell-therapy reports.

## Summary

Nature Medicine appears monthly and publishes phase 1 and 2 trials with deep translational analysis (MagnetisMM-3 elranatamab in this corpus), circulating tumour DNA and multi-cancer early-detection studies, large medical-AI validations and consensus reporting guidelines for AI in medicine. Hybrid access with a Springer Nature open-access option.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: Nat Med; src-nature-medicine
- Publisher: Springer Nature
- Scope: translational medicine
- Access: hybrid

## Notes

- Holds: Translational medicine including cancer vaccines, AI diagnostics and phase 1 to 3 trials with mechanistic depth. Access: Paywalled; abstracts free; some open access.

## Sources

- Nature Medicine cancer: https://www.nature.com/nm/research-articles?subject=cancer

## Connected records

- key papers: [89 Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer](https://onco.cc/key-papers/paper-bensch-nat-med/), [A foundation model for clinical-grade computational pathology and rare cancers detection](https://onco.cc/key-papers/paper-vorontsov-nat-med/), [A visual-language foundation model for computational pathology](https://onco.cc/key-papers/paper-lu-nat-med/), [Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M](https://onco.cc/key-papers/paper-thress-nat-med/), [Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms](https://onco.cc/key-papers/paper-durham-nat-med/), [Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial](https://onco.cc/key-papers/paper-relativity-098-nat-med-2025/), [Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial](https://onco.cc/key-papers/paper-chrysalis-nat-med-2023/), [An anti-PMEL antibody-drug conjugate with a G q/1 1 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial](https://onco.cc/key-papers/paper-nct05415072-nat-med-2026/), [Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial](https://onco.cc/key-papers/paper-nct03178552-nat-med-2022/), [Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial](https://onco.cc/key-papers/paper-nct03334617-nat-med-2024/), [Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab](https://onco.cc/key-papers/paper-gandara-blood-tmb-atezolizumab-nat-med-2018/), [Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial](https://onco.cc/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/), [Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules](https://onco.cc/key-papers/paper-mitsunaga-nat-med/), [Cancer stem cells revisited](https://onco.cc/key-papers/paper-batlle-nat-med/), [Cancer stem cells: mirage or reality?](https://onco.cc/key-papers/paper-gupta-nat-med/), [Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial](https://onco.cc/key-papers/paper-tutt-nat-med/), [CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint](https://onco.cc/key-papers/paper-cepheus-dara-vrd-natmed-2025/), [CheckMate 76K: adjuvant nivolumab in resected stage IIB or IIC melanoma](https://onco.cc/key-papers/paper-checkmate-76k-nat-med-2023/), [Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial](https://onco.cc/key-papers/paper-dynamic-nat-med-2025-update/), [Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial (TRIUMPH)](https://onco.cc/key-papers/paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021/), [CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial](https://onco.cc/key-papers/paper-mackensen-nat-med/), [Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial](https://onco.cc/key-papers/paper-dawna-1-nat-med-2021/), [Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer](https://onco.cc/key-papers/paper-beltran-nepc-divergent-evolution-nat-med-2016/), [Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial](https://onco.cc/key-papers/paper-mahalingam-nat-med/), [Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial](https://onco.cc/key-papers/paper-breakwater-nat-med-2025/), [EXPLORER: safety and efficacy of avapritinib in advanced systemic mastocytosis (phase 1)](https://onco.cc/key-papers/paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021/), [Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial](https://onco.cc/key-papers/paper-mimic-01-nat-med-2023/), [First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial](https://onco.cc/key-papers/paper-nct05227664-nat-med-2026/), [First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial](https://onco.cc/key-papers/paper-nct05351788-nat-med-2025/), [GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold](https://onco.cc/key-papers/paper-galaxy-signatera-nat-med-2023/), [Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial](https://onco.cc/key-papers/paper-rodon-nat-med/), [Glecirasib in KRAS G12C -mutated nonsmall-cell lung cancer: a phase 2b trial](https://onco.cc/key-papers/paper-nct05009329-nat-med-2025/), [GLOW: zolbetuximab plus CAPOX in claudin 18.2-positive, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma](https://onco.cc/key-papers/paper-glow-zolbetuximab-nat-med-2023/), [Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial](https://onco.cc/key-papers/paper-nct05671510-nat-med-2026/), [How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals](https://onco.cc/key-papers/paper-wu-nat-med/), [HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures](https://onco.cc/key-papers/paper-davies-nat-med/), [Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell](https://onco.cc/key-papers/paper-bonnet-nat-med/), [Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial](https://onco.cc/key-papers/paper-nct04606446-nat-med-2024/), [JUPITER-02: toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma](https://onco.cc/key-papers/paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021/), [Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis](https://onco.cc/key-papers/paper-romero-nat-med/), [Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial](https://onco.cc/key-papers/paper-brown-nat-med/), [Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial](https://onco.cc/key-papers/paper-pant-nat-med/), [MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response](https://onco.cc/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/), [Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results](https://onco.cc/key-papers/paper-nct03907852-nat-med-2023/), [Molecular determinants of resistance to antiandrogen therapy](https://onco.cc/key-papers/paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004/), [Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study](https://onco.cc/key-papers/paper-sicklick-nat-med/), [Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes](https://onco.cc/key-papers/paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018/), [MYC targeting by OMO-103 in solid tumors: a phase 1 trial](https://onco.cc/key-papers/paper-garralda-nat-med/), [Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers](https://onco.cc/key-papers/paper-niche-2-nat-med-2020/), [Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial](https://onco.cc/key-papers/paper-nct04497844-nat-med-2025/), [Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial](https://onco.cc/key-papers/paper-dizman-nat-med/), [PATHFINDER: efficacy and safety of avapritinib in advanced systemic mastocytosis (phase 2 interim analysis)](https://onco.cc/key-papers/paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021/), [Pembrolizumab and chemotherapy in high-risk, early-stage, ER + /HER2 - breast cancer: a randomized phase 3 trial](https://onco.cc/key-papers/paper-nct03725059-nat-med-2025/), [Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial](https://onco.cc/key-papers/paper-nhs-galleri-performance-nat-med-2026/), [Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial](https://onco.cc/key-papers/paper-impassion031-nat-med-2025-update/), [Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial](https://onco.cc/key-papers/paper-nct05061550-nat-med-2025/), [Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial](https://onco.cc/key-papers/paper-burd-nat-med/), [Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial](https://onco.cc/key-papers/paper-nct05347134-nat-med-2025/), [Stojdl 2000: cancer cells that stopped answering interferon cannot stop a virus either](https://onco.cc/key-papers/paper-stojdl-vsv-interferon-defect-natmed-2000/), [Substantial interindividual and limited intraindividual genomic diversity among tumours from men with metastatic prostate cancer](https://onco.cc/key-papers/paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016/), [Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy](https://onco.cc/key-papers/paper-collisson-pancreatic-subtypes-nat-med-2011/), [The consensus molecular subtypes of colorectal cancer](https://onco.cc/key-papers/paper-cms-guinney-nat-med-2015/), [The molecular landscape of paediatric acute myeloid leukaemia (TARGET)](https://onco.cc/key-papers/paper-bolouri-paediatric-aml-genomics-nat-med-2018/), [The NCI-MATCH trial: lessons for precision oncology](https://onco.cc/key-papers/paper-o-dwyer-nat-med/), [The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial](https://onco.cc/key-papers/paper-kilburn-nat-med/), [Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial](https://onco.cc/key-papers/paper-elara-tisagenlecleucel-follicular-nat-med-2022/), [Todo 2022: the triple-mutated herpes virus that became Japan's first approved oncolytic virus](https://onco.cc/key-papers/paper-todo-g47delta-glioblastoma-natmed-2022/), [Towards a general-purpose foundation model for computational pathology](https://onco.cc/key-papers/paper-chen-nat-med/), [Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial](https://onco.cc/key-papers/paper-destiny-breast04-nat-med-2025-update/), [Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial](https://onco.cc/key-papers/paper-destiny-breast12-nat-med-2024/), [TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases](https://onco.cc/key-papers/paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022/), [Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study](https://onco.cc/key-papers/paper-rothwell-nat-med/), [Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study](https://onco.cc/key-papers/paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019/), [Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression](https://onco.cc/key-papers/paper-bissell-nat-med/)
- people: [Harlan M. Krumholz](https://onco.cc/people/harlan-krumholz/), [Pavan Reddy](https://onco.cc/people/pavan-reddy/), [Ulrich G. Steidl](https://onco.cc/people/ulrich-steidl/), [Victor Piana de Andrade](https://onco.cc/people/victor-piana-de-andrade/)

---
JSON: https://onco.cc/api/v1/entities/nature-medicine.json